Results 101 to 110 of about 3,225,994 (369)

Tumor angiogenesis: causes, consequences, challenges and opportunities

Cellular and Molecular Life Sciences, 2019
Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same cancer tissue. These processes are orchestrated by a range of secreted
R. Lugano, Mohanraj Ramachandran, A. Dimberg   +2 more
semanticscholar   +1 more source

Ezetimibe Is an Inhibitor of Tumor Angiogenesis [PDF]

The American Journal of Pathology, 2009
Epidemiological and preclinical observations have suggested a role for one or more products of the mevalonate/cholesterol biosynthesis pathway in the progression of prostate cancer. In this study, we used ezetimibe (Zetia), a specific, FDA-approved, cholesterol uptake-blocking drug, in combination with either a hyper- or hypocholesterolemic diet, to ...
Jinsoo Joo, Keith R. Solomon, Keith R. Solomon, Kelly Boucher, Jayoung Kim, Jayoung Kim, Carl P. Schaffner, Kristine Pelton, David Zurakowski, Christopher Tully, Michael R. Freeman, Michael R. Freeman   +11 more
openaire   +2 more sources

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture [PDF]

, 2015
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established ...
Fraga-Silva, Rodrigo, Stergiopulos, Nikolaos, Trachet, Bram   +2 more
core   +2 more sources

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

MicroRNA-145 Regulates Pathological Retinal Angiogenesis by Suppression of TMOD3

Molecular Therapy: Nucleic Acids, 2019
Pathological angiogenesis is a hallmark of various vascular diseases, including vascular eye disorders. Dysregulation of microRNAs (miRNAs), a group of small regulatory RNAs, has been implicated in the regulation of ocular neovascularization.
Chi-Hsiu Liu, Zhongxiao Wang, Shuo Huang, Ye Sun, Jing Chen   +4 more
doaj   +1 more source

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. [PDF]

, 2020
Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response.
Boichard, Amélie, Kurzrock, Razelle, Li, Alex M   +2 more
core  

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Inhibitory antibodies designed for matrix metalloproteinase modulation [PDF]

, 2019
The family of matrix metalloproteinases (MMPs) consists of a set of biological targets that are involved in a multitude of severe pathogenic events such as different forms of cancers or arthritis.
Fischer, Thomas, Riedl, Rainer
core   +1 more source

Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology

Molecular Oncology, EarlyView.
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee Clark, Hong Wang, Belinda Phipson, Andrew Bakshi, Andrew Ryan, Heather Thorne, Renea A. Taylor, Mitchell G. Lawrence, Gail P. Risbridger, Roxanne Toivanen, David L. Goode   +12 more
wiley   +1 more source